Doyle SK, Pop MS, Evans HL, Koehler AN. Advances in discovering small molecules to probe protein function in a systems context. Curr Opin Chem Biol. 2016;30:28-36. doi:10.1016/j.cbpa.2015.10.032
Dandapani S, Marcaurelle LA. Current strategies for diversity-oriented synthesis. Curr Opin Chem Biol. 2010;14(3):362-70. doi:10.1016/j.cbpa.2010.03.018
Bennett DA, Yu L, De Jager PL. Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer’s disease. Biochem Pharmacol. 2014;88(4):617-30. doi:10.1016/j.bcp.2014.01.037
Kato N, Comer E, Sakata-Kato T, et al. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature. 2016;538(7625):344-349. doi:10.1038/nature19804
Koehler AN. A complex task? Direct modulation of transcription factors with small molecules. Curr Opin Chem Biol. 2010;14(3):331-40. doi:10.1016/j.cbpa.2010.03.022
Walcott BP, Peterson RT. Zebrafish models of cerebrovascular disease. J Cereb Blood Flow Metab. 2014;34(4):571-7. doi:10.1038/jcbfm.2014.27
Wagner BK. The resurgence of phenotypic screening in drug discovery and development. Expert Opin Drug Discov. 2016;11(2):121-5. doi:10.1517/17460441.2016.1122589
Golub T. Counterpoint: Data first. Nature. 2010;464(7289):679. doi:10.1038/464679a
Hyman SE. Time for new schizophrenia Rx. Science. 2014;343(6176):1177. doi:10.1126/science.1252603
Johannessen CM, Clemons PA, Wagner BK. Integrating phenotypic small-molecule profiling and human genetics: the next phase in drug discovery. Trends Genet. 2015;31(1):16-23. doi:10.1016/j.tig.2014.11.002